专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010064223A2 CYTOKINES AS PROGNOSTIC MARKERS OF RESPIRATORY-TRACT INFECTION FOLLOWING MAJOR SURGERY 审中-公开
标题翻译：细胞因子作为主要手术后呼吸道感染的预防标记
公开(公告)号：WO2010064223A2
公开(公告)日：2010-06-10
申请号：PCT/IE2009000085
申请日：2009-11-30
申请人： TRINITY COLLEGE DUBLIN , RYAN THOMAS , WHITE MARY , MCMANUS OWEN ROSS , KELLEHER DERMOT , STORDEUR PATRICK , YOUNG VINCENT
发明人： RYAN THOMAS , WHITE MARY , MCMANUS OWEN ROSS , KELLEHER DERMOT , STORDEUR PATRICK , YOUNG VINCENT
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/158 , G06F19/18 , G06F19/3431 , G16H50/30
摘要： The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-IO, and Interferon-? (INF?) and Tissue Necrosis Factor-a (TNFa). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset. Typically, cytokine abundance is expressed in terms of mRNA copy number wherein the copy numbers are ideally normalised to a house keeping gene and quantification of mRNA copy number is determined by RT-PCR containing reference serial dilutions of cytokine specific cDNA.
摘要翻译：本发明涉及某些亚细胞因子标记物在个体中作为感染状态的预后变量的用途，特别是作为手术后发生严重感染如肺炎和呼吸道感染的患者的预后标志物。细胞因子标志物的亚组由IL-2，IL-7，IL-23，IL-27和IL-10以及干扰素（INF？）和组织坏死因子-α（TNFa）。标记物可以用作感染状态的个体预后变量，或者它们可以成对使用或其它组合使用。通常，标记物的丰度与生物标志物丰度的绝对术前价值，手术前与术后生物标志物丰度的比值或子集内特定生物标志物对的比值相关联于感染状态。通常，细胞因子丰度以mRNA拷贝数表示，其中拷贝数理想地归一化为保存基因，并且通过含有细胞因子特异性cDNA的参考连续稀释度的RT-PCR测定mRNA拷贝数的定量。

2. 发明申请

WO2006005910A3 PHARMACEUTICAL COMPOSITION COMPRISING BOTULINUM, A NON IONIC SURFACTANT, SODIUM CHLORIDE AND SUCROSE 审中-公开
公开(公告)号：WO2006005910A3
公开(公告)日：2006-01-19
申请号：PCT/GB2005/002653
申请日：2005-07-06
申请人： IPSEN LIMITED , WEBB, Paul , WHITE, Mary , PARTINGTON, Julie
发明人： WEBB, Paul , WHITE, Mary , PARTINGTON, Julie
IPC分类号： A61K38/48 , A61K47/30
摘要： The invention relates to a solid or liquid pharmaceutical composition comprising botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G), and a surfactant. In particular the invention relates to a solid or liquid pharmaceutical composition comprising a crystalline agent.

3. 发明申请

WO2003080108A1 STABLE PHARMACEUTICAL COMPOSITION CONTAINING FACTOR VIII 审中-公开
标题翻译：含有因子VIII的稳定药用组合物
公开(公告)号：WO2003080108A1
公开(公告)日：2003-10-02
申请号：PCT/GB2003/001297
申请日：2003-03-26
申请人： SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) , WHITE, Mary , WEBB, Paul
发明人： WHITE, Mary , WEBB, Paul
IPC分类号： A61K38/37
CPC分类号： A61K9/19 , A61K9/0019 , A61K38/37 , A61K47/02 , A61K47/18 , A61K47/26
摘要： The invention relates to a stable solid pharmaceutical composition comprising factor VIII. Such a composition is devoid of amino acids and comprises: (a) factor VIII; (b) a surfactant; (c) calcium chloride; (d) sucrose; (e) sodium chloride; (f) trisodium citrate; and (g) a buffer devoid of amino acids; and has a pH from 6 to 8 prior to lyophilisation and after reconstitution in water for injection. The invention also relates to the liquid pharmaceutical composition obtainable after dilution of said stable solid pharmaceutical composition with sterile water optionally containing sodium chloride.
摘要翻译：本发明涉及包含因子VIII的稳定的固体药物组合物。这种组合物没有氨基酸，并且包括：（a）因子VIII; （b）表面活性剂; （c）氯化钙; （d）蔗糖; （e）氯化钠; （f）柠檬酸三钠; 和（g）没有氨基酸的缓冲液; 并且在冻干之前和在用于注射的水中重构后具有6至8的pH。本发明还涉及在用任选含有氯化钠的无菌水稀释所述稳定的固体药物组合物后可获得的液体药物组合物。

4. 发明申请

WO2010064223A3 CYTOKINES AS PROGNOSTIC MARKERS OF RESPIRATORY-TRACT INFECTION FOLLOWING MAJOR SURGERY 审中-公开
公开(公告)号：WO2010064223A3
公开(公告)日：2010-06-10
申请号：PCT/IE2009/000085
申请日：2009-11-30
申请人： THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN , RYAN, Thomas , WHITE, Mary , McMANUS, Owen Ross , KELLEHER , Dermot , STORDEUR, Patrick , YOUNG, Vincent
发明人： RYAN, Thomas , WHITE, Mary , McMANUS, Owen Ross , KELLEHER , Dermot , STORDEUR, Patrick , YOUNG, Vincent
IPC分类号： C12Q1/68
摘要： The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-IO, and Interferon-γ (INFγ) and Tissue Necrosis Factor-α (TNFα). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset. Typically, cytokine abundance is expressed in terms of mRNA copy number wherein the copy numbers are ideally normalised to a house keeping gene and quantification of mRNA copy number is determined by RT-PCR containing reference serial dilutions of cytokine specific cDNA.

5. 发明申请

WO2010041232A3 A METHOD OF ESTIMATING SEPSIS RISK IN AN INDIVIDUAL WITH INFECTION 审中-公开
标题翻译：估计感染个体感染风险的方法
公开(公告)号：WO2010041232A3
公开(公告)日：2010-06-03
申请号：PCT/IE2009000070
申请日：2009-10-09
申请人： TRINITY COLLEGE DUBLIN , RYAN THOMAS , WHITE MARY , MCMANUS OWEN ROSS , KELLEHER DERMOT
发明人： RYAN THOMAS , WHITE MARY , MCMANUS OWEN ROSS , KELLEHER DERMOT
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/158
摘要： A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk using a regression analysis curve against outcome.
摘要翻译：评估患有感染个体的败血症风险的方法包括测定来自个体的IL-2或IL-7mRNA值的生物样品，并将mRNA值与败血症风险相关联的步骤。通过mRNA拷贝数的绝对定量来定量IL-2和IL-7mRNA值，其中拷贝数被归一化到家庭保持基因，并且针对用于连续稀释IL-2和IL-7 cDNA的校准曲线进行校正。该方法通常包括从个体测定IL-2和/或IL-7mRNA值的生物学样品的步骤，任选地与其它细胞因子的mRNA值组合，并且将该值与脓毒病风险的总和或差值相关联，使用对结果的回归分析曲线。

6. 发明申请

WO2010041232A2 A METHOD OF ESTIMATING SEPSIS RISK IN AN INDIVIDUAL WITH INFECTION 审中-公开
标题翻译：感染个体中脓毒症风险的评估方法
公开(公告)号：WO2010041232A2
公开(公告)日：2010-04-15
申请号：PCT/IE2009/000070
申请日：2009-10-09
申请人： THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN , RYAN, Thomas , WHITE, Mary , MCMANUS, Owen Ross , KELLEHER, Dermot
发明人： RYAN, Thomas , WHITE, Mary , MCMANUS, Owen Ross , KELLEHER, Dermot
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/158
摘要： A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk using a regression analysis curve against outcome.
摘要翻译：估计患有感染的个体的脓毒症风险的方法包括测定来自个体的生物样品的IL-2或IL-7mRNA值，并将该mRNA值与脓毒症风险相关联的步骤。通过对mRNA拷贝数进行绝对定量来量化IL-2和IL-7mRNA值，其中将拷贝数归一化为管家基因并针对IL-2和IL-7cDNA的连续稀释的校准曲线进行校正。该方法通常包括测定来自个体的生物样品中IL-2和/或IL-7mRNA值的步骤，任选地与其他细胞因子的mRNA值组合，并将这些值的总和或差异与使用脓毒症风险相关联一个对结果的回归分析曲线。

7. 发明申请

WO2019010565A1 PHASE-CHANGE MATERIAL AND METHOD FOR PRODUCING SAME 审中-公开
公开(公告)号：WO2019010565A1
公开(公告)日：2019-01-17
申请号：PCT/CA2018/050704
申请日：2018-06-12
申请人： NOËL, John Alexander , WHITE, Mary Anne
发明人： NOËL, John Alexander , WHITE, Mary Anne
IPC分类号： C09K5/06
摘要： A method for producing a form-stable phase-change material includes freezing a slurry of solid and solvent to provide a frozen slurry, exposing the frozen slurry to conditions causing sublimation of the frozen solvent to remove solvent and provide a body having vacancies therein, sintering the body to provide a scaffold, and adding a molten phase-change material to the scaffold to provide the form-stable phase-change material. The same scaffold when ground acts as a phase-change nucleating aid.

8. 发明申请

WO2006005910A2 PHARMACEUTICAL COMPOSITION CONTAINING BOTULINUM NEUROTOXIN 审中-公开
标题翻译：含有神经毒素的药物组合物
公开(公告)号：WO2006005910A2
公开(公告)日：2006-01-19
申请号：PCT/GB2005002653
申请日：2005-07-06
申请人： IPSEN LTD , WEBB PAUL , WHITE MARY , PARTINGTON JULIE
发明人： WEBB PAUL , WHITE MARY , PARTINGTON JULIE
IPC分类号： A61K38/38 , A61K9/00 , A61K9/19 , A61K38/48 , A61K47/26
CPC分类号： A61K9/0019 , A61K9/19 , A61K38/4886 , A61K38/4893 , A61K47/26 , C12Y304/24069 , A61K2300/00
摘要： The invention relates to a solid or liquid pharmaceutical composition comprising botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G), and a surfactant. In particular the invention relates to a solid or liquid pharmaceutical composition comprising a crystalline agent.
摘要翻译：本发明涉及包含肉毒杆菌神经毒素复合物（A，B，C，D，E，F或G型）或高纯度肉毒杆菌神经毒素（A，B，C，D，E，F或G型）的固体或液体药物组合物）和表面活性剂。特别地，本发明涉及包含结晶剂的固体或液体药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式